Developer docs
API playgroundTry for free, no card

Search company profiles

Procyrion

Full company profile

uuid00025bw

Namestring
Procyrion
Legal namestring
Procyrion, Inc.
Websiteurl
procyrion.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Procyrion, Inc. is a privately held, clinical-stage medical device company founded in 2005 and headquartered in Houston, Texas, that is developing Aortix™, a catheter-deployed percutaneous mechanical circulatory support (pMCS) device intended for hospitalized heart failure patients with concurrent renal dysfunction (cardiorenal syndrome). Aortix is placed in the descending thoracic aorta between the heart and renal arteries and uses a proprietary fluid entrainment mechanism — high-velocity jets that accelerate native blood flow — to pump blood without a valve, simultaneously reducing cardiac workload by decreasing afterload and increasing renal perfusion. The device is less than 6mm in diameter, delivers up to 7 days of circulatory support, and is designed for percutaneous deployment in under 10 minutes via femoral access using self-expanding nickel-titanium anchors.

The company's business model is a pre-revenue medical device hardware sales model contingent on regulatory approval. Procyrion has not yet commercialized Aortix and does not have publicly disclosed pricing; the device remains investigational in the U.S. and is limited to clinical investigations in the European Union. The company has raised over $133.7 million cumulatively across grants, Series C ($16M, 2018), Series D ($30M, 2019), and Series E ($57.7M, 2024), led by Fannin Partners and Bluebird Ventures, and holds FDA Breakthrough Device Designation (July 2019) and ISO 13485:2016 certification. It is currently enrolling the DRAIN-HF pivotal IDE trial to support a future PMA submission.

Procyrion is preparing for commercialization through enterprise hospital sales into cardiac catheterization labs and mechanical circulatory support programs, supplemented by KOL engagement at major cardiovascular conferences and clinical publications. The intended customers are hospitals treating acute decompensated heart failure (ADHF) patients — a market exceeding 6 million U.S. adults affected by heart failure, over 1.8 million HF hospitalizations annually, and $100+ billion in global annual spend — with primary focus on the cardiorenal syndrome subpopulation where up to 64% of ADHF hospitalizations involve renal dysfunction. The company operates with 11-50 employees, draws leadership from former Abbott/St. Jude Medical, Thoratec, Silk Road Medical, and Medtronic executives, and is led by President & CEO Eric S. Fain, MD.

Short descriptiontext

Procyrion is a clinical-stage Houston-based medical device company developing Aortix™, a catheter-deployed percutaneous circulatory support pump that simultaneously unloads the heart and perfuses the kidneys to treat acute decompensated heart failure patients with cardiorenal syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
percutaneous circulatory support, cardiac assist devices, heart failure therapy, mechanical circulatory support, cardiorenal syndrome treatment
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Assist Devices (Percutaneous Mechanical Circulatory Support)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Procyrion is a pre-commercial medical device company developing the Aortix pMCS device. The company has not yet generated revenue as the device is in clinical development and not approved for sale. Upon regulatory approval, the company will commercialize through hospital/healthcare system sales channels.

procyrion.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Aortix™
Description

Percutaneous mechanical circulatory support (pMCS) device designed to treat heart failure patients who are too sick for medication alone. The device is placed in the descending thoracic aorta via catheter and harnesses fluid entrainment to pump blood without the need for a valve.

procyrion.com
Core offering1 text field

Procyrion develops the Aortix™ percutaneous mechanical circulatory support (pMCS) device — a catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload and increase renal perfusion. The investigational device is designed to treat acute decompensated heart failure (ADHF) patients with cardiorenal syndrome who have failed medical therapy. The device is currently in clinical development (DRAIN-HF pivotal IDE trial) and is not approved for commercial sale in any country.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduced heart workload by almost 40% in pre-clinical studies
+4 more records
Product overview1 text field

Procyrion is developing a single core product, the Aortix™ percutaneous mechanical circulatory support (pMCS) device, which is a catheter-deployed intra-aortic pump technology. The Aortix system is designed to simultaneously rest the heart by reducing afterload and improve renal perfusion by accelerating blood flow to the kidneys. The device uses a unique fluid entrainment mechanism that pumps blood without requiring a valve, and is designed for deployment in less than 10 minutes via a percutaneous catheter procedure. The product is currently in clinical development (IDE pivotal trial phase) and is not yet approved for commercial sale.

Product and service1 record
1Aortix™ Percutaneous Mechanical Circulatory Support (pMCS) Device
CategoryCardiac Assist Devices / Mechanical Circulatory Support
Description

A catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload (afterload) and increase renal perfusion simultaneously. Designed for percutaneous deployment in under 10 minutes via the femoral artery, with self-expanding nickel-titanium anchors securing the pump to the aortic wall. Provides up to 7 days of circulatory support and is intended for hospitalized acute decompensated heart failure (ADHF) patients with worsening renal function (cardiorenal syndrome) who have failed medical therapy. Currently in clinical development (DRAIN-HF pivotal IDE trial); investigational and not approved for sale in any country.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Acquired by Abbott in 2023, Abiomed markets the Impella family of percutaneous mechanical circulatory support devices, which is the most directly competing catheter-based pMCS platform to Aortix in the heart failure and cardiogenic shock space.

TypeBroad incumbent
Description

Through its Arrow division, Teleflex manufactures intra-aortic balloon pumps (IABP), the established standard-of-care for percutaneous mechanical circulatory support that Aortix aims to displace in cardiorenal syndrome patients.

TypeBroad incumbent
Description

Getinge's Maquet division provides intra-aortic balloon counterpulsation therapy and ECMO systems, making it an established incumbent in the broader percutaneous mechanical circulatory support market where Aortix competes.

TypeBroad incumbent
Description

LivaNova acquired the TandemHeart pMCS platform and offers mechanical circulatory support solutions for cardiogenic shock and heart failure, competing in the same cath-lab-based pMCS space as Aortix.

5Abbott
TypeBroad incumbent
Description

Beyond Impella, Abbott offers HeartMate left ventricular assist devices and a broad cardiovascular portfolio including IABP, making it a major incumbent across the entire mechanical circulatory support landscape in which Procyrion operates.

TypeBroad incumbent
Description

Fresenius acquired Xenios to provide ECMO and cardiopulmonary support technologies, making it a broad incumbent in mechanical circulatory support adjacent to Aortix's cath-lab-based pMCS focus.

TypeBroad incumbent
Description

Terumo offers advanced cardiovascular and interventional products including circulatory support devices and catheter-based technologies, making it a relevant broad incumbent in the cath-lab interventional space where Aortix will commercialize.

TypeBroad incumbent
Description

Edwards Lifesciences is a leader in structural heart and heart failure therapies, and is developing transcatheter heart failure solutions that may overlap with or compete against Aortix in the advanced heart failure treatment space.

TypeEmerging player
Description

Cardiobridge developed the Reitan catheter-based circulatory support system for percutaneous support, representing another emerging European pMCS technology with overlapping indication space in acute heart failure and cardiorenal applications.

TypeEmerging player
Description

Magenta Medical is developing transcatheter heart pump technologies for acute heart failure with similar miniaturization and percutaneous delivery goals as Aortix, making it an emerging peer in the next-generation pMCS category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Procyrion

Cardiac Assist Devices (Percutaneous Mechanical Circulatory Support)procyrion.com

Procyrion is a clinical-stage Houston-based medical device company developing Aortix™, a catheter-deployed percutaneous circulatory support pump that simultaneously unloads the heart and perfuses the kidneys to treat acute decompensated heart failure patients with cardiorenal syndrome.

What Procyrion does

Procyrion, Inc. is a privately held, clinical-stage medical device company founded in 2005 and headquartered in Houston, Texas, that is developing Aortix™, a catheter-deployed percutaneous mechanical circulatory support (pMCS) device intended for hospitalized heart failure patients with concurrent renal dysfunction (cardiorenal syndrome). Aortix is placed in the descending thoracic aorta between the heart and renal arteries and uses a proprietary fluid entrainment mechanism — high-velocity jets that accelerate native blood flow — to pump blood without a valve, simultaneously reducing cardiac workload by decreasing afterload and increasing renal perfusion. The device is less than 6mm in diameter, delivers up to 7 days of circulatory support, and is designed for percutaneous deployment in under 10 minutes via femoral access using self-expanding nickel-titanium anchors.

The company's business model is a pre-revenue medical device hardware sales model contingent on regulatory approval. Procyrion has not yet commercialized Aortix and does not have publicly disclosed pricing; the device remains investigational in the U.S. and is limited to clinical investigations in the European Union. The company has raised over $133.7 million cumulatively across grants, Series C ($16M, 2018), Series D ($30M, 2019), and Series E ($57.7M, 2024), led by Fannin Partners and Bluebird Ventures, and holds FDA Breakthrough Device Designation (July 2019) and ISO 13485:2016 certification. It is currently enrolling the DRAIN-HF pivotal IDE trial to support a future PMA submission.

Procyrion is preparing for commercialization through enterprise hospital sales into cardiac catheterization labs and mechanical circulatory support programs, supplemented by KOL engagement at major cardiovascular conferences and clinical publications. The intended customers are hospitals treating acute decompensated heart failure (ADHF) patients — a market exceeding 6 million U.S. adults affected by heart failure, over 1.8 million HF hospitalizations annually, and $100+ billion in global annual spend — with primary focus on the cardiorenal syndrome subpopulation where up to 64% of ADHF hospitalizations involve renal dysfunction. The company operates with 11-50 employees, draws leadership from former Abbott/St. Jude Medical, Thoratec, Silk Road Medical, and Medtronic executives, and is led by President & CEO Eric S. Fain, MD.

Procyrion firmographics

Firmographics
Name
Procyrion
Legal name
Procyrion, Inc.
Website
https://procyrion.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Procyrion is a clinical-stage Houston-based medical device company developing Aortix™, a catheter-deployed percutaneous circulatory support pump that simultaneously unloads the heart and perfuses the kidneys to treat acute decompensated heart failure patients with cardiorenal syndrome.
Ownership category
akta.pro rank

Procyrion industry classification

Industry
Product category
Cardiac Assist Devices (Percutaneous Mechanical Circulatory Support)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Percutaneous circulatory support
  • Cardiac assist devices
  • Heart failure therapy
  • Mechanical circulatory support
  • Cardiorenal syndrome treatment

Where Procyrion is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Procyrion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: Procyrion is a pre-commercial medical device company developing the Aortix pMCS device. The company has not yet generated revenue as the device is in clinical development and not approved for sale. Upon regulatory approval, the company will commercialize through hospital/healthcare system sales channels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Procyrion product offering

Product offering

Core offering

Procyrion develops the Aortix™ percutaneous mechanical circulatory support (pMCS) device — a catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload and increase renal perfusion. The investigational device is designed to treat acute decompensated heart failure (ADHF) patients with cardiorenal syndrome who have failed medical therapy. The device is currently in clinical development (DRAIN-HF pivotal IDE trial) and is not approved for commercial sale in any country.

Product overview

Procyrion is developing a single core product, the Aortix™ percutaneous mechanical circulatory support (pMCS) device, which is a catheter-deployed intra-aortic pump technology. The Aortix system is designed to simultaneously rest the heart by reducing afterload and improve renal perfusion by accelerating blood flow to the kidneys. The device uses a unique fluid entrainment mechanism that pumps blood without requiring a valve, and is designed for deployment in less than 10 minutes via a percutaneous catheter procedure. The product is currently in clinical development (IDE pivotal trial phase) and is not yet approved for commercial sale.

Differentiator

Problem solved

Functional benefit

Brands

  • Aortix™: Percutaneous mechanical circulatory support (pMCS) device designed to treat heart failure patients who are too sick for medication alone. The device is placed in the descending thoracic aorta via catheter and harnesses fluid entrainment to pump blood without the need for a valve.

Products and services

  • Aortix™ Percutaneous Mechanical Circulatory Support (pMCS) Device A catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload (afterload) and increase renal perfusion simultaneously. Designed for percutaneous deployment in under 10 minutes via the femoral artery, with self-expanding nickel-titanium anchors securing the pump to the aortic wall. Provides up to 7 days of circulatory support and is intended for hospitalized acute decompensated heart failure (ADHF) patients with worsening renal function (cardiorenal syndrome) who have failed medical therapy. Currently in clinical development (DRAIN-HF pivotal IDE trial); investigational and not approved for sale in any country.

Quantifiable outcome

  • Reduced heart workload by almost 40% in pre-clinical studies
  • +4 more outcomes

Companies that use Procyrion

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Procyrion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Procyrion partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Procyrion competitors and assessment

Company assessment

Direct peers

  • Abiomed (Abbott): Acquired by Abbott in 2023, Abiomed markets the Impella family of percutaneous mechanical circulatory support devices, which is the most directly competing catheter-based pMCS platform to Aortix in the heart failure and cardiogenic shock space.

Broad incumbents

  • Teleflex: Through its Arrow division, Teleflex manufactures intra-aortic balloon pumps (IABP), the established standard-of-care for percutaneous mechanical circulatory support that Aortix aims to displace in cardiorenal syndrome patients.
  • Getinge (Maquet): Getinge's Maquet division provides intra-aortic balloon counterpulsation therapy and ECMO systems, making it an established incumbent in the broader percutaneous mechanical circulatory support market where Aortix competes.
  • LivaNova: LivaNova acquired the TandemHeart pMCS platform and offers mechanical circulatory support solutions for cardiogenic shock and heart failure, competing in the same cath-lab-based pMCS space as Aortix.
  • Abbott: Beyond Impella, Abbott offers HeartMate left ventricular assist devices and a broad cardiovascular portfolio including IABP, making it a major incumbent across the entire mechanical circulatory support landscape in which Procyrion operates.
  • Fresenius Medical Care (Xenios): Fresenius acquired Xenios to provide ECMO and cardiopulmonary support technologies, making it a broad incumbent in mechanical circulatory support adjacent to Aortix's cath-lab-based pMCS focus.
  • Terumo: Terumo offers advanced cardiovascular and interventional products including circulatory support devices and catheter-based technologies, making it a relevant broad incumbent in the cath-lab interventional space where Aortix will commercialize.
  • Edwards Lifesciences: Edwards Lifesciences is a leader in structural heart and heart failure therapies, and is developing transcatheter heart failure solutions that may overlap with or compete against Aortix in the advanced heart failure treatment space.

Emerging players

  • Cardiobridge: Cardiobridge developed the Reitan catheter-based circulatory support system for percutaneous support, representing another emerging European pMCS technology with overlapping indication space in acute heart failure and cardiorenal applications.
  • Magenta Medical: Magenta Medical is developing transcatheter heart pump technologies for acute heart failure with similar miniaturization and percutaneous delivery goals as Aortix, making it an emerging peer in the next-generation pMCS category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Procyrion social profiles

Digital presence

Procyrion compliance and trust

Trust signal

Compliance2 records

Procyrion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Procyrion leadership team

Management profile

Number of profiles

Profiles12 records

Procyrion funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Procyrion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Procyrion

What does Procyrion do?

Procyrion develops the Aortix™ percutaneous mechanical circulatory support (pMCS) device — a catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload and increase renal perfusion. The investigational device is designed to treat acute decompensated heart failure (ADHF) patients with cardiorenal syndrome who have failed medical therapy. The device is currently in clinical development (DRAIN-HF pivotal IDE trial) and is not approved for commercial sale in any country.

Is Procyrion a public or private company?

Procyrion is a private company. It is classified as venture growth investor backed and is currently operating.

When was Procyrion founded?

Procyrion was founded in 2005. It employs 11 to 50 people.

Where is Procyrion based?

Procyrion is headquartered in Houston, United States, in the North America region.

How does Procyrion make money?

One revenue line is on record: medical Device Sales.

Who are Procyrion's main competitors?

Abiomed (Abbott) is listed as a direct peer. Broad incumbents are Teleflex, Getinge (Maquet), LivaNova, Abbott, Fresenius Medical Care (Xenios), Terumo and Edwards Lifesciences. Emerging players are Cardiobridge and Magenta Medical.

Does Procyrion have an API?

No public API is recorded for Procyrion.

What industry is Procyrion in?

Procyrion's product category is Cardiac Assist Devices (Percutaneous Mechanical Circulatory Support). Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerProcyrion names Jason Whiting as CEOProcyrion appointed Jason Whiting as CEO, succeeding Eric S. Fain, who will remain on the board. The company's DRAIN-HF trial for its Aortix device continues enrolling patients with acute decompensated heart failure. Whiting will focus on completing enrollment, regulatory approval, and commercialization.openPR.comIn-Depth Examination of Segments, Industry Trends, and Key Competitors in the Percutaneous Mechanical Circulatory Support Devices MarketThe percutaneous mechanical circulatory support devices market is projected to reach $3.87 billion by 2030, growing at a 9.4% CAGR, driven by advances in AI-driven cardiac monitoring, complex cardiac interventions, and catheterization laboratory expansion. In April 2023, Abbott Laboratories acquired Cardiovascular Systems Inc. (CSI) for approximately $890 million to expand its vascular portfolio with CSI's orbital atherectomy systems and percutaneous mechanical circulatory support technologies. Additionally, Procyrion Inc. successfully performed the first-in-human use of its Aortix pump in February 2023, designed to prevent acute kidney injury during cardiac surgery by improving renal perfusion.PR NewswireProcyrion Appoints Andrew Davis as Chief Commercial OfficerProcyrion appointed Andrew Davis as Chief Commercial Officer to lead therapy development and trial enrollment for its Aortix device. In this role, Davis will focus on advancing the DRAIN-HF pivotal IDE trial and preparing for the future commercialization of the Aortix percutaneous mechanical circulatory support technology. The appointment aims to strengthen efforts to address unmet needs in patients with diuretic-resistant heart failure.The American Bazaar -Dr. Atul Varadhachary: Building a bridge between scientific discovery and biotech commercializationDr. Atul Varadhachary, Managing Partner at Fannin Innovation, discusses the firm's biotech investment model, which focuses on early-stage drug development and grants. Fannin has raised over $260 million across its programs and is preparing for exits, including Procyrion's FDA approval next year. He also highlights the potential for replicating the model in India.Pulse 2.0Procyrion Raises $57.7 Million To Improve Outcomes For Patients With Cardiac ImpairmentProcyrion raised $57.7 million in a Series E round, led by Fannin Partners, to fund the DRAIN-HF pivotal trial for its Aortix device in acute decompensated heart failure patients with cardiorenal syndrome. The company also plans to use funds for manufacturability and commercialization, citing up to 25% rehospitalization or mortality at 30 days for untreated patients.G-MedtechProcyrion Closes $57.7 Million Series E FinancingProcyrion has closed a $57.7 million Series E financing round led by Fannin Partners and followed by Bluebird Ventures to support its Aortix device development. The capital will fund the pivotal DRAIN-HF clinical trial for acute decompensated heart failure patients with cardiorenal syndrome, as well as efforts to improve manufacturability and prepare for commercialization.Cardiovascular BusinessHeart failure specialists raise $58M for new device designed to improve cardiac, renal functionHouston-based healthcare technology company Procyrion has raised $57.7 million in Series E funding to support research and commercialization of its Aortix percutaneous mechanical circulatory support device. The funds will primarily finance the DRAIN-HF clinical trial, which evaluates the device's safety and effectiveness in treating acute decompensated heart failure patients with cardiorenal syndrome.FinSMEsProcyrion Closes $57.7M in Series E FundingHouston-based medical device company Procyrion closed a $57.7 million Series E funding round, which included the conversion of $10.0 million in interim financing. The capital will be used to support the pivotal DRAIN-HF IDE trial for its Aortix device, improve manufacturability, and prepare for commercialization. The round was led by Fannin Partners with participation from Bluebird Ventures and other investors.PR NewswireProcyrion Closes $57.7 Million in Series E FinancingProcyrion Inc. completed a $57.7 million Series E financing round led by Fannin Partners to support its DRAIN-HF pivotal IDE trial for the Aortix device and commercialization preparations. The funds will also be used to improve the manufacturability of the Aortix percutaneous mechanical circulatory support device, which targets patients with acute decompensated heart failure and cardiorenal syndrome.Medical BuyerProcyrion closes $57.7M in Series E financingProcyrion, Inc. has closed a $57.7 million Series E funding round led by Fannin Partners to support the DRAIN-HF pivotal trial for its Aortix device and commercialization preparations. The capital will be used to evaluate the percutaneous mechanical circulatory support device in patients with acute decompensated heart failure and cardiorenal syndrome who do not respond to standard therapy.